Back to Search
CATHLEEN SMALL, PH.D., BCBA-D
PH.D., BCBA-D
Psychologist
NPI: 1649475682IndividualAccepts Medicare
Specialties, Licenses & Credentials
PsychologistPrimary
Psychologist
Code: 103T00000X
04783(MD)PS1380(ME)
Behavior Analyst
Behavior Analyst
Code: 103K00000X
1-05-2441
CMS Specialties
PrimaryCLINICAL PSYCHOLOGIST
Education
OTHER
Class of 2007
Clinical Trials (1)
1
Linked Trials
0
Recruiting
1
With Results
Research & Publications (20)
Bictegravir/Emtricitabine/Tenofovir Alafenamide: A Review in HIV-1 Infection.
PMID 30460547·Drugs·2018
6-review
Switching to fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide from dolutegravir plus abacavir and lamivudine in virologically suppressed adults with HIV-1: 48 week results of a randomised, double-blind, multicentre, active-controlled, phase 3, non-inferiority trial.
PMID 29925489·Lancet HIV·2018
3-trial
Efficacy and safety of switching from boosted protease inhibitors plus emtricitabine and tenofovir disoproxil fumarate regimens to single-tablet darunavir, cobicistat, emtricitabine, and tenofovir alafenamide at 48 weeks in adults with virologically suppressed HIV-1 (EMERALD): a phase 3, randomised, non-inferiority trial.
PMID 28993180·Lancet HIV·2018
3-trial
Bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection (GS-US-380-1489): a double-blind, multicentre, phase 3, randomised controlled non-inferiority trial.
PMID 28867497·Lancet·2017
3-trial
Bictegravir versus dolutegravir, each with emtricitabine and tenofovir alafenamide, for initial treatment of HIV-1 infection: a randomised, double-blind, phase 2 trial.
PMID 28219610·Lancet HIV·2017
3-trial
Long-acting combination anti-HIV drug suspension enhances and sustains higher drug levels in lymph node cells than in blood cells and plasma.
PMID 28099191·AIDS·2017
7-preclinical
Emtricitabine-Triphosphate in Dried Blood Spots as a Marker of Recent Dosing.
PMID 27572401·Antimicrob Agents Chemother·2016
1-meta
Switching to Tenofovir Alafenamide, Coformulated With Elvitegravir, Cobicistat, and Emtricitabine, in HIV-Infected Patients With Renal Impairment: 48-Week Results From a Single-Arm, Multicenter, Open-Label Phase 3 Study.
PMID 26627107·J Acquir Immune Defic Syndr·2016
3-trial
Pharmacokinetics of long-acting tenofovir alafenamide (GS-7340) subdermal implant for HIV prophylaxis.
PMID 25896688·Antimicrob Agents Chemother·2015
7-preclinical
A National Study of Outcomes among HIV-Infected Kidney Transplant Recipients.
PMID 25791727·J Am Soc Nephrol·2015
8-other
Quantitation of tenofovir and emtricitabine in dried blood spots (DBS) with LC-MS/MS.
PMID 24055850·J Pharm Biomed Anal·2014
8-other
Tenofovir, emtricitabine, and tenofovir diphosphate in dried blood spots for determining recent and cumulative drug exposure.
PMID 22935078·AIDS Res Hum Retroviruses·2013
8-other
Pharmacological considerations for tenofovir and emtricitabine to prevent HIV infection.
PMID 21118913·J Antimicrob Chemother·2011
6-review
Outcomes of kidney transplantation in HIV-infected recipients.
PMID 21083386·N Engl J Med·2010
3-trial
Maternal exposure to a brominated flame retardant and genitourinary conditions in male offspring.
PMID 19654930·Environ Health Perspect·2009
8-other
NK cells play a critical protective role in host defense against acute extracellular Staphylococcus aureus bacterial infection in the lung.
PMID 18390740·J Immunol·2008
7-preclinical
Onset of symptomatic effect of mometasone furoate nasal spray in the treatment of nasal polyposis.
PMID 18234321·J Allergy Clin Immunol·2008
4-observational
Judicious antibiotic use and intranasal corticosteroids in acute rhinosinusitis.
PMID 17398218·Am J Med·2007
6-review
Risk of spontaneous abortion among women exposed to polybrominated biphenyls.
PMID 17239850·Environ Res·2007
8-other
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 301C US ROUTE 1
SCARBOROUGH, ME 04074 - Phone
- (207) 396-8600
Quick Facts
- NPI
- 1649475682
- Entity Type
- Individual
- Gender
- Female
- Medicare
- Accepted
- Specialties
- 3
- Locations
- 1
- Years in Practice
- 19
- Clinical Trials
- 1
- Publications
- 20
Are you this provider?
Claim Your Profile